Procavea Biotech AG
Innovative molecular delivery solutions for medicine
Procavea Biotech is on a mission to transform RNA therapeutic delivery with its groundbreaking OP platform: a first-of-its-kind, nonviral protein cage designed for efficient siRNA transport. By tackling the limitations of current delivery technologies, we aspire to unlock the full potential of siRNA-based drugs, expanding their reach beyond the liver and into previously untreatable diseases. In doing so, we are not just creating new treatments - we are helping to reshape the future of precision medicine.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
31.10.2025
More than 20 Swiss biotech companies to exhibit at Bio Europe (startupticker.ch)
15.05.2024
TOP 18 startups contest further for the >>venture>> Award (startupticker.ch)
No Jobs
No videos and documents
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Procavea Biotech AG
Innovative molecular delivery solutions for medicine
Website:
www.procavea.com
Headquarter:
Zürich ETH-Hönggerberg
Foundation Date:
February 2024
Technology:
- Biotech
Sectors:
- Biotech
- Drug development platforms
- Drug discovery
- Protein drugs
- Small molecule drugs
Support received
